Oral biologics constitute a novel group of drugs that have been gaining popularity over the last few decades. Key players in the oral biologics market are working to develop and market oral biologics, however safety of the protein from degradation and digestion in the gastrointestinal tract has been recognized as one of the major concerns. The ease and familiarity of this route of administration is the most noticeable advantage for the majority of patients. It is also expected that the availability of biologics in the form of oral pills can increase the rate of compliance and patient satisfaction, which will greatly improve the health of patients by adjusting the course of the disease and avoiding further complications. In addition, oral biologics may also reduce the cost of treatment and increase access thus improving the health of millions of people with chronic disease globally.
Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_sample.php?id=780
Growing alliances and partnerships between market players are expected to create a favorable environment for the growth of the global oral biologics market. For instance, in 2016, Rani Therapeutics announced a partnership with Medimmune, a research and development subsidiary of AstraZeneca, to test Rani Therapeutics new oral drug delivery platform. This partnership is anticipated to promote drug feasibility trials and test biological molecules in the field of metabolic disease in order to assess the oral delivery of molecules. The aim of this partnership is to orally deliver biologics in order to increase and enhance patient compliance. In another instance, in April 2018, Emisphere Technologies, Inc. updated its production and license agreement with Novo Nordisk A/S, for the development and commercialization of oral formulations using Emisphere's oral Eligen Technology.
Major market players are investing towards research and development, which is expected to fuel the growth of the global oral biologics market over the forecast period. For example, researchers at the Massachusetts Institute of Technology (MIT) created a drug capsule in 2019, with the potential to deliver an oral insulin called SOMA capsule, replacing the need for type 1 diabetes patients to administer insulin by injections multiple times a day. The researchers suggested that the drugs are currently being tested in preclinical trials and are expected to reach clinical trials by 2022.
Enquiry Before Buying @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=780
The effect of COVID-19 on the global oral biologics market has been significant. Both pharmaceutical firms and academic agencies, are searching for a safe cure for the disease with the spiking number of COVID positive cases. The oral biologics market has therefore witnessed a massive inflow of funds for the same purpose. Apeiron Biologics of Vienna raised money in June 2020, to support the research and production of its drug APN01, which is believed to be a COVID-19 cure. The funds will be used in Austria, Germany, Denmark and the UK for the Phase II production of this biologic drug. The company raised funds from current and new private and institutional investors, including the Vienna Insurance Group (VIG), which invested about EUR 7 million in APEIRON Biologics for a 3.26% stake. The Austrian Research Agency (FFG), the Vienna Business Agency (WAW), the Austrian Economic Service Company (AWS) and Erste Bank have also pledged a total of EUR 5.6 million in public funding with guarantees.
In terms of revenue, global oral biologics market was valued at US$ 1103.62 Mn in 2019 and is anticipated to grow at a CAGR of 15.9% over the forecast period (2020 - 2028). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
The detailed research study provides qualitative and quantitative analysis of oral biologics market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Request for Customization@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=780
Key Findings of the Report:
- A substantial influx of funds in the oral biologics market in 2020 is being directed towards the development of drugs for the treatment of COVID-19. Investment initiative in this scale is expected to showcase positive growth trajectory for the global market over the coming years.
- North America held the dominant position in the global oral biologics market. The U.S. is projected to be the most profitable market for oral biologics, since it is the largest pharmaceutical market with a large number of players. In addition, high spending on healthcare, and high acceptance rate of novel drugs make oral biologics the most prominent market in the United States.
- The major players operating in the market include AbbVie Inc., Allena Pharmaceuticals, Inc., Gilead Sciences, Inc., Intertek Group plc, McKesson Corporation, Novo Nordisk A/S, Pfizer Inc., Rani Therapeutics and Veloce Digital Health amongst other market participants.
Global Oral Biologics Market:
- By Offering
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Combination Drugs
- Others
- By Therapeutic Area
- Inflammatory Bowel Disease
- Diabetes
- Ulcerative Colitis and Crohn Disease
- Acromegaly and Neuroendocrine Tumours
- Osteoporosis
- Inflammatory disease
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Get Full Information of this premium report@ https://www.absolutemarketsinsights.com/reports/Oral-Biologics-2020---2028-780
About Us:
Absolute Markets Insights strives to be your main man in your business resolve by giving you insight into your products, market, marketing, competitors, and customers. Visit …
Contact Us:
Email id: [email protected]
Contact Name: Shreyas Tanna
Phone: +91-740-024-2424